Àẹ °áÇÙ °Ë»ç ½ÃÀå : ÇöȲ ºÐ¼®°ú ¿¹Ãø(2024-2032³â)
Latent TB Testing Market: Current Analysis and Forecast (2024-2032)
»óǰÄÚµå : 1634626
¸®¼­Ä¡»ç : UnivDatos Market Insights Pvt Ltd
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,999 £Ü 5,674,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,499 £Ü 7,803,000
PDF (Site License - Up to 5 Users) help
PDF º¸°í¼­¸¦ µ¿Àϱâ¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,932,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àẹ°áÇÙ °Ë»ç ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È CAGR 7.8%%ÀÇ »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÁÖ·Î Àü ¼¼°è¿¡¼­ °áÇÙ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ȱµ¿¼º °áÇÙÀ» ¿¹¹æÇϱâ À§ÇØ Àẹ°áÇÙÀ» °ËÃâÇÒ Çʿ伺ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ IGRA¿Í °°Àº Áø´Ü ÅøÀÇ °³¼±À¸·Î °íÀ§Ç豺¿¡¼­ÀÇ È¿°ú¿Í Ȱ¿ëµµ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤ºÎ°¡ Áö¿øÇÏ´Â °áÇÙ ¿¹¹æ Ä·ÆäÀΰú °ËÁø Àǹ«È­µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°Ë»ç À¯Çü¿¡ µû¶ó ½ÃÀåÀº Åõº£¸£Ä𸰠¹ÝÀÀ °Ë»ç(TST)¿Í ÀÎÅÍÆä·Ð ¥ã ¹æÃâ ÃøÁ¤¹ý(IGRA)À¸·Î ±¸ºÐµË´Ï´Ù. ÀÎÅÍÆä·Ð ¥ã ¹æÃâ ÃøÁ¤¹ý(IGRA)Àº 2023³â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÎÅÍÆä·Ð ¥ã ¹æÃâ ÃøÁ¤¹ý(IGRA)Àº °í¼Òµæ ±¹°¡¿Í º¸È£°¡ ÇÊ¿äÇÑ »ç¶÷µé »çÀÌ¿¡¼­ °ÅÀÇ µ¶Á¡ÀûÀ¸·Î ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ IGRA´Â QuantiFERON-TB ¹× T-SPOT.TB¿Í °°Àº º¸´Ù Á¤¹ÐÇÑ »õ·Î¿î °Ë»ç¸¦ Á¦°øÇϰí Áø´Ü ÇÁ·Î¼¼½º ÀÚµ¿È­ÀÇ È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ ±â¾÷¿¡¼­ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á±â°ü°ú Çù·ÂÇÏ¿© Á¤±â °ËÁø¿¡ IGRA¸¦ µµÀÔÇϰí, PoA¿¡¼­ IGRAÀÇ È°¿ëµµ¸¦ ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Á¤È®ÇÑ Áø´Ü Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ôÀ¸¸ç, ÀÌ ±â¼úÀº ÇöÀç¿Í ¹Ì·¡ÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ³ôÀº °ü·Ã¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

2024³â 3¿ù 18ÀÏ, QIAGEN(NYSE: QGEN;Frankfurt Prime Standard: QIA)Àº ±¹Á¦ÆÐ³ÎÀÇ»çÇùȸ(IPPA)¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇØ Àü ¼¼°è ÆÐ³Î ÀÇ»çµé¿¡°Ô ÃֽаáÇÙ °ËÁø ¿ä°Ç¿¡ ´ëÇÑ Áö¿ø ¹× ±³À°À» Á¦°øÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ƯÈ÷ »õ·Î¿î ÀÎÅÍÆä·Ð¥ã ¹æÃâ ÃøÁ¤¹ý(IGRA)ÀÇ ¿ä°Ç°ú °ü·Ã ȯÀÚ ¹× ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ÇýÅÿ¡ ÃÊÁ¡À» ¸ÂÃâ ¿¹Á¤ÀÔ´Ï´Ù.

¿ëµµº°·Î´Â °áÇ٠ȯÀÚÀÇ °¡Á¤³» Á¢ÃËÀÚ(HHC), HIV °¨¿°ÀÚ(PLHIV), ±âŸ·Î ±¸ºÐµÇ¸ç, HIV °¨¿°ÀÚ´Â ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, PLHIV ȯÀڴ Ȱµ¿¼º °áÇÙ ¹ßº´ À§ÇèÀÌ ³ô±â ¶§¹®¿¡ Á¤±âÀûÀ̰í Á¤È®ÇÑ °Ë»ç°¡ ÇÊ¿äÇϸç, Àẹ°áÇÙ °Ë»çÀÇ ÃÖ´ë ¼ÒºñÀÚÀÔ´Ï´Ù. ÃÖ±Ù Àü ¼¼°è¿¡¼­ HIV Ä¡·á ÇÁ·Î±×·¥¿¡¼­ °áÇÙ Áø´ÜÀÌ È®´ëµÊ¿¡ µû¶ó IGRA¿Í °°Àº ¼ºº°¿¡ ´ëÇÑ Á¤È®Çϰí Á¤¹ÐÇÑ °Ë»çÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº HIV Áø·á¼Ò ¹× NGO¿Í ÆÄÆ®³Ê½ÊÀ» ¸Î¾î ƯÁ¤ °Ë»ç ¼Ö·ç¼ÇÀ» Á¦°øÇϰí, ÀÌ °íÀ§Ç豺¿¡°Ô Àú·ÅÇÏ°í °£ÆíÇÑ ±Ô¸ðÀÇ °Ë»ç ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ ±×·ì¿¡ ÀûÇÕÇÑ °Ë»ç ¼Ö·ç¼ÇÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ½ÃÀåÀº Áø´Ü ½ÇÇè½Ç, º´¿ø/Áø·á¼Ò, Çмú ¹× ¿¬±¸±â°üÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â ½ÃÀå¿¡¼­´Â Áø´Ü ½ÇÇè½ÇÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áø´Ü ½ÇÇè½ÇÀº ƯÈ÷ µµ½Ã ¹× ¹Ýµµ½Ã Áö¿ªÀÇ Àẹ°áÇÙ °Ë»ç ¼¾Åͷμ­ ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù. °í±Þ Áø´Ü Àåºñ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ°í °á°úÀÇ Á¤È®¼ºÀ» º¸ÀåÇÔÀ¸·Î½á ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®À» Áö¿øÇϱâ À§ÇØ ±â¾÷Àº IGRA ÀÚµ¿È­ ½Ã½ºÅÛÀ» °ø±Þ ¹× ¼³Ä¡Çϰí, È¿À²ÀûÀÎ ½ÇÇè½Ç ¿î¿µÀ» À§ÇÑ ¼Ö·ç¼ÇÀ» µµÀÔÇϰí, °á°ú¸¦ ÀÓ»ó ȯ°æ¿¡ ½±°Ô ÅëÇÕÇÒ ¼ö ÀÖ´Â ±â¼úÀ» Á¦°øÇÕ´Ï´Ù.

Àẹ°áÇÙ °Ë»ç ½ÃÀå µµÀÔ¿¡ ´ëÇÑ ÀÌÇØ¸¦ µ½±â À§ÇØ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ±âŸ Áö¿ª(Áß±¹, ÀϺ», Àεµ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), Àü ¼¼°è Á¸À縦 ±â¹ÝÀ¸·Î ºÐ¼®µË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ³ôÀº °áÇÙ ¹ßº´·ü, °áÇÙ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, °áÇÙ ÅðÄ¡¸¦ À§ÇÑ ±¹°¡Àû ³ë·Â¿¡ ±âÀÎÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2022³â¿¡´Â 8°³ ±¹°¡°¡ Àü ¼¼°è °áÇ٠ȯÀÚÀÇ 3ºÐÀÇ 2 ÀÌ»óÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÈ´Ù: Àεµ(27%), Àεµ³×½Ã¾Æ(10%), Áß±¹(7.1%), Çʸ®ÇÉ(7.0%), ÆÄŰ½ºÅº(5.7%), ³ªÀÌÁö¸®¾Æ(4.5), ³ªÀÌÁö¸®¾Æ(4.5)%), ¹æ±Û¶óµ¥½Ã(3.6%), Äá°í¹ÎÁÖ°øÈ­±¹(3.0%)ÀÔ´Ï´Ù. ¶ÇÇÑ Àεµ¿Í Áß±¹ µî¿¡¼­´Â ±¹Á¦±â±¸ÀÇ Çù·ÂÀ» ÅëÇØ ´ë±Ô¸ð °ËÁøÀ» ½Ç½ÃÇß½À´Ï´Ù. ¿¹¸¦ µé¾î Àúºñ¿ë Áø´Ü ¼Ö·ç¼Ç Á¦°ø, Á¤ºÎ ±â°ü°úÀÇ Á¦ÈÞ, Á¦Ç° Á¢±ÙÀÌ Á¦ÇÑµÈ Áö¿ª¿¡ ´ëÇÑ ½ÃÀå ¹üÀ§ Çâ»ó µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. µµ½Ã Áö¿ª¿¡¼­´Â ±âÁ¸ TST¿¡¼­ ÷´Ü IGRA·Î ÀüȯÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷¿¡´Â QIAGEN, Revvity, Abbott, BIOMERIEUX, Serum Institute of India Pvt.Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå °³¿ä

Á¦2Àå ºÐ¼® ¹æ¹ý ¶Ç´Â ÀüÁ¦Á¶°Ç

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå °¡°Ý ºÐ¼®

Á¦6Àå ¼¼°èÀÇ Àẹ °áÇÙ °Ë»ç ½ÃÀå ¸ÅÃâ(2022-2032³â)

Á¦7Àå ½ÃÀå ºÐ¼® : °Ë»ç À¯Çüº°

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦9Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå µÎÀÚ¾î¿Í ÀüÁ¦Á¶°Ç

Á¦15Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Latent TB Testing determines individuals with asymptomatic Mycobacterium tuberculosis infection who are likely to develop overt TB. Screening tests include the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs), which identify a body's reaction to the bacteria. These tests are important in the prevention of TB epidemics among multiple risk groups such as the immunocompromised as well as the healthcare givers.

The Latent TB Testing Market is expected to grow with a significant CAGR of 7.8% during the forecast period (2024-2032). This is mainly due to the increasing rates of tuberculosis across the world increasing the need to detect latent TB to prevent active TB. Also, improvements in diagnostic tools like IGRAs increase the effectiveness and utilization in high-risk groups. In addition, TB control campaigns supported by the government and compulsory screening norms also contribute to the growth of the market.

Based on the test type, the market is segmented into Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA). The Interferon Gamma Released Assay (IGRA) held a significant share of the market in 2023. The Interferon Gamma Released Assay (IGRA). It is implemented almost exclusively in high-income countries and among the populations in need of protection. Adding to this, IGRA is used by companies to provide new, more precise tests, such as QuantiFERON-TB and T-SPOT.TB, and to increase the efficiency of diagnostic process automation. They aim to cooperate with healthcare organizations to include IGRAs in regular check-ups and increase the availability of IGRAs via point of care. This technology has high relevance in the current and future healthcare systems since there is a great need for accurate diagnostic equipment.

On March 18, 2024, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.

Based on application, the market is segmented into household contacts (HHC) of tuberculosis (TB) patients, people living with HIV (PLHIV), and others. People living with HIV are expected to grow with a significant CAGR during the forecast period (2024-2032). The PLHIV segment is one of the primary consumers in the latent TB testing market because such patients have a higher risk of developing active TB and, therefore, require regular and accurate tests. The recent expansion of tuberculosis diagnostics in HIV care programs worldwide has boosted the need for gender-precise and accurate tests such as IGRAs. Companies adopt by developing partnerships with HIV clinics and NGOs to deliver specific test solutions and by providing affordable easy-to-scale testing solutions to this risky group.

Based on the end user, the market is segmented into diagnostic laboratories, hospitals/clinics, and academic & research institutions. Diagnostic Laboratories held a significant share of the market in 2023. Diagnostic laboratories are major players as the testing centers for latent TB, especially in urban and semi-urban settings. They enhance growth by expanding access to high-level diagnostic equipment and guaranteeing the accuracy of results. To support this segment, companies supply and install IGRA automation systems, implement solutions for efficient lab operations, and provide technology for easy integration of the results into the clinical environment.

For a better understanding of the market adoption of Latent TB Testing, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is due to a high tuberculosis incidence rate, improved understanding of the disease, and national efforts to eliminate the disease. As per the World Health Organization, In 2022, eight countries accounted for more than two-thirds of global TB cases: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%). Adding to this, large-scale screening is being carried out in countries such as India and China with the help of international organizations. Examples include offering low-cost diagnostic solutions, forming alliances with government organizations, and increasing market coverage to areas that have limited access to the products. A shift from conventional TSTs to advanced IGRAs within the urban regions also supports the growth of the market.

Some of the major players operating in the market include QIAGEN, Revvity, Abbott, BIOMERIEUX, Serum Institute of India Pvt. Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

2.RESEARCH METHODOLOGY OR ASSUMPTION

3.EXECUTIVE SUMMARY

4.MARKET DYNAMICS

5.PRICING ANALYSIS

6.GLOBAL LATENT TB TESTING MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY TEST TYPE

8.MARKET INSIGHTS BY APPLICATION

9.MARKET INSIGHTS BY END USER

10.MARKET INSIGHTS BY REGION

11.VALUE CHAIN ANALYSIS

12.COMPETITIVE LANDSCAPE

13.COMPANY PROFILES

14.ACRONYMS & ASSUMPTION

15.ANNEXURE

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â